Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Novartis Pharmaceuticals Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

NCT02267135
View directory record Official record
Conditions
Chronic Scalp Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

NCT00782067
View directory record Official record
Conditions
Leukemia
Interventions
Midostaurin (PKC412)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

NVA237 Versus Placebo 12-week Efficacy Study

NCT01709864
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
54
States / cities
Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Jun 7, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus Versus Placebo in Head and Neck Cancer

NCT01111058
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Everolimus (RAD 001), Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Miami, Florida • Chicago, Illinois • Harvey, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

NCT01572727
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, BKM120 matching placebo, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jun 7, 2026, 5:01 AM EDT
Active, not recruiting Phase 2 Interventional

Ribociclib (LEE011) Rollover Study for Continued Access

NCT02934568
View directory record Official record
Conditions
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

NCT00171158
View directory record Official record
Conditions
Philadelphia Chromosome Positive CML
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jun 7, 2026, 5:01 AM EDT
Terminated Phase 1 Interventional Results available

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

NCT01642732
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, lupron, bicalutamide, and radiation
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)

NCT05328752
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions
XXB750, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Inverness, Florida • Jacksonville, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 7, 2026, 5:01 AM EDT
Terminated Phase 4 Interventional Results available

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04878211
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Hollywood, Florida • Wellesley, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

NCT03066648
View directory record Official record
Conditions
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases, Chronic Myelomonocytic Leukemia
Interventions
Decitabine, PDR001, MBG453, Azacitidine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jun 7, 2026, 5:01 AM EDT
Not listed Phase 2 Interventional

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10Mg Tab
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

NCT02178540
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, Tobi Podhaler
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 1Phase 2 Interventional

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

NCT00846989
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983A, Latanoprost
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Artesia, California • Inglewood, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 7, 2026, 5:01 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178
View directory record Official record
Conditions
Advanced HER2+Breast Cancer
Interventions
Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Fayetteville, Arkansas • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 7, 2026, 5:01 AM EDT
Terminated Phase 1 Interventional

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

NCT02734615
View directory record Official record
Conditions
Advanced or Metastatic ER+ Breast Cancer
Interventions
LSZ102, LEE011, BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

NCT01950481
View directory record Official record
Conditions
Normal Hepatic Function, Impaired Hepatic Function
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Lakewood, Colorado • DeLand, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

NCT00446511
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

NCT01124864
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Rockville, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

NCT00079001
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
238
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis

NCT02151864
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis
Interventions
LDE225
Drug
Lead sponsor
Jason K. Sicklick, M.D.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

NCT01582061
View directory record Official record
Conditions
Cushing's Disease
Interventions
Pasireotide sub-cutaneous
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jun 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041
View directory record Official record
Conditions
Non-transfusion Dependent Thalassemia
Interventions
deferasirox, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Jun 7, 2026, 5:01 AM EDT